S Ketamine Use in Total Abdominal Hysterectomy

Brief Summary

This study investigates the effect of low dose S+ketamine compared to placebo on cumulative morphine consumption at 24 hours in women undergoing open abdominal hysterectomy with remifentanil-propofol target controlled infusion. It compares the adverse effect profile in patients receiving S+ketamine as compared to those who did not. Participants are randomly distributed in two groups of 45 patient's each.

Intervention / Treatment

  • Drug: S Ketamine

Condition or Disease

  • Total Abdominal Hysterectomy

Phase

Study Design

Study type: Interventional
Status: Withdrawn
Study results: No Results Available
Age: 21 Years and older   (Adult, Older Adult)
Enrollment: 0 ()
Funded by: Other

Masking

Clinical Trial Dates

Start date: Jun 14, 2022
Primary Completion: Jun 15, 2022
Completion Date: Jun 15, 2022
Study First Posted: Sep 07, 2015
Results First Posted: Aug 31, 2020
Last Updated: Sep 07, 2015

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

In recent times it has been suggested that NMDA receptor antagonist like ketamine when used in small doses helps reducing postoperative pain and opioid consumption without compromising wakefulness and or causing its psycho mimetic adverse effect .

The clinical utility of S+ ketamine as an adjuvant intra-operatively remains controversial. The NMDA receptor activation and subsequent biochemical process has been proven to play an important role in both hyperalgesia after tissue injury and the development of opioid tolerance. Various studies have reported the advantage of S+ ketamine over traditional balanced anaesthesia, but may lead to secondary hyperalgesia and increased opioid requirement in post operative period in both animals and healthy human volunteers. Other studies showed that 48 hours continuous administration of small-dose ketamine, together with patient-controlled analgesia (PCA) with morphine, or systemic, epidural co-administration of ketamine and opiates markedly reduced cumulative morphine. However, the dosage, route and timing of administration of S+-ketamine varied in different setting.

Eligibility Criteria

Sex: Female
Minimum Age: 21

More Details

NCT Number: NCT02543385
Acronym: SKET
Other IDs: 2008/905/D
Study URL: https://ClinicalTrials.gov/show/NCT02543385
Last updated: Jun 17, 2022